Last updated: September 7, 2026
Filgotinib is a selective Janus kinase 1 (JAK1) inhibitor developed by Galapagos NV and commercialized with Gilead Sciences as Jyseleca. It reached approval in the European Union and Japan for rheumatoid arthritis and ulcerative colitis, but its commercial outlook deteriorated after the U.S. regulatory setback, class-wide JAK safety restrictions, and the 2024 withdrawal of its European marketing authorization. Filgotinib is no longer positioned as a major global growth asset.
What is the current development status of filgotinib?
Filgotinib is commercially available only in a limited number of markets and is no longer being developed as a broad global immunology product.
| Item |
Status |
| Active ingredient |
Filgotinib |
| Product brand |
Jyseleca |
| Pharmacology |
Selective JAK1 inhibitor |
| Originator |
Galapagos NV |
| Commercial partner |
Gilead Sciences |
| Main indications |
Rheumatoid arthritis and ulcerative colitis |
| EU status |
Marketing authorization withdrawn at the company’s request in 2024 |
| U.S. status |
Not approved |
| Japan status |
Approved for rheumatoid arthritis |
| Primary development risk |
JAK-class safety restrictions and reproductive-safety concerns |
| Commercial direction |
Wind-down and rights transition rather than expansion |
The European Commission authorized Jyseleca in September 2020 for adults with moderate-to-severe active rheumatoid arthritis who had inadequate response or intolerance to one or more disease-modifying antirheumatic drugs. The authorization covered 200 mg and 100 mg once-daily tablets, with restrictions affecting the 200 mg dose in certain patients (European Commission, 2020).
The European label was later expanded to include moderate-to-severe active ulcerative colitis in adults who had inadequate response, lost response, or were intolerant to conventional treatment or biologic therapy (European Medicines Agency, 2021).
Galapagos and Gilead ended their global collaboration in 2024. Galapagos resumed responsibility for Jyseleca in Europe and announced the withdrawal of the product from the European market. The European Medicines Agency subsequently recorded the withdrawal of the marketing authorization at the request of the marketing authorization holder for commercial reasons (European Medicines Agency, 2024).
When did filgotinib receive regulatory approval?
Filgotinib achieved regulatory approval in Europe and Japan but failed to obtain U.S. approval.
European Union approval
The European Commission granted marketing authorization for Jyseleca on September 24, 2020. The initial approval covered rheumatoid arthritis. The product label included risk-management provisions relating to:
- Serious infections
- Malignancy
- Major adverse cardiovascular events
- Venous thromboembolism
- Reproductive and fertility considerations
- Use in older patients and patients with cardiovascular or malignancy risk factors
The European authorization was commercially important because the European market represented the principal approved western market for filgotinib after the U.S. regulatory setback.
Ulcerative colitis approval
The European Commission extended the Jyseleca indication to ulcerative colitis in 2021. The indication was based principally on the SELECTION Phase 2b/3 program, which evaluated induction and maintenance treatment in patients with moderate-to-severe ulcerative colitis.
The ulcerative-colitis approval increased the potential addressable population but did not materially change the product’s competitive position against established JAK inhibitors and biologics.
Japan approval
Japan approved filgotinib for rheumatoid arthritis in 2020. The Japanese market remained strategically relevant because the product avoided the complete loss of commercial access that occurred in the United States. Japan’s approval did not offset the loss of the U.S. opportunity or the later European withdrawal.
United States regulatory outcome
The U.S. Food and Drug Administration issued a complete response letter in 2020 for the rheumatoid arthritis application. The principal issues involved the benefit-risk profile, long-term safety data, and the impact of the MANTA and MANTA-Ray studies evaluating semen parameters in male patients.
Gilead did not resubmit filgotinib in the United States. The product therefore has no U.S. NDA approval and no U.S. commercial launch.
What is the Orange Book status of filgotinib?
Filgotinib has no U.S. Orange Book listing because the FDA has not approved a filgotinib product.
That status has several consequences:
- There is no U.S. reference product with an approved NDA against which an ANDA applicant can directly certify.
- There is no U.S. Orange Book patent-listing strategy for filgotinib.
- A conventional Paragraph IV litigation pathway has not developed around an approved U.S. filgotinib product.
- U.S. generic entry is not the immediate commercial issue because the product lacks an approved U.S. market.
Any future U.S. development would require a regulatory strategy centered on a new NDA, resubmission, or other FDA pathway rather than ordinary generic substitution.
What patents protect filgotinib?
Filgotinib is protected by a layered patent estate covering the active compound, pharmaceutical compositions, therapeutic uses, dosing, and manufacturing-related subject matter. The principal commercial patent value was concentrated in Europe and Japan because the United States never reached approval.
Core patent categories
| Patent category |
Commercial purpose |
Relative importance |
| Composition-of-matter patents |
Protect filgotinib and related chemical entities |
Highest |
| Pharmaceutical composition patents |
Protect tablet and formulation use |
Medium |
| Method-of-treatment patents |
Cover rheumatoid arthritis and ulcerative colitis treatment |
Medium |
| Dosing patents |
Address patient selection, dose levels, and safety-related use |
Medium |
| Process patents |
Protect selected manufacturing routes or intermediates |
Low to medium |
| Combination patents |
Cover use with other immunomodulatory agents |
Selective |
Public Galapagos materials described filgotinib patent protection in key markets extending into the late 2020s or around 2030, subject to jurisdiction-specific prosecution, supplementary protection certificates, patent-term adjustments, and national validity. The exact effective date differs by patent family and country. The relevant protection is therefore not a single global expiration date.
Because filgotinib is a small molecule, the key follow-on threat is generic competition rather than biosimilar competition. Regulatory exclusivity and patent coverage are separate. Generic filgotinib manufacturers could challenge composition, formulation, method-of-use, or process patents where those rights remain enforceable.
How strong is the filgotinib patent estate?
The estate is commercially meaningful but weakened by the product’s limited geographic footprint.
Its strengths are:
- Early compound protection for a selective JAK1 inhibitor
- Multiple indication and formulation filings
- Approval in jurisdictions where patent enforcement is generally predictable
- Potential SPC or patent-term extensions in some European countries
Its weaknesses are:
- No U.S. commercial product
- No U.S. Orange Book leverage
- A relatively narrow remaining commercial window after 2024
- Reduced incentive for generic challengers while the market is being withdrawn
- Possible design-around opportunities involving salts, formulations, manufacturing routes, or dosing regimens
The estate is stronger as a defensive asset than as a platform for major incremental revenue.
When does filgotinib lose exclusivity?
Filgotinib’s practical loss of exclusivity will vary by country and patent family. The core protection is generally understood to extend into the late 2020s or approximately 2030 in major markets, with possible extensions in individual jurisdictions.
The more important commercial event occurred before formal patent expiry: withdrawal of the European marketing authorization. A product can retain enforceable patents while generating little or no branded revenue if the originator exits the market.
| Period |
Event |
| 2020 |
European Union rheumatoid arthritis approval |
| 2020 |
FDA complete response letter; no U.S. launch |
| 2020 |
Japan rheumatoid arthritis approval |
| 2021 |
European ulcerative colitis approval |
| 2022-2023 |
Commercial sales in Europe and Japan under Jyseleca |
| 2024 |
Gilead-Galapagos collaboration ended |
| 2024 |
EU marketing authorization withdrawn |
| Late 2020s to around 2030 |
Expected core patent expiry window in major jurisdictions, subject to national rights |
A formal patent-expiry analysis requires review of each national family member, granted claims, terminal disclaimers, SPCs, pediatric extensions, and post-grant proceedings. Public company disclosures support a late-2020s to approximately 2030 framework rather than one universal expiration date.
Were there Paragraph IV challenges to filgotinib?
No material U.S. Paragraph IV challenge has been publicly associated with filgotinib.
The reason is regulatory rather than patent-related. Filgotinib never obtained FDA approval, so no U.S. generic applicant had a standard approved reference product and Orange Book listing around which to construct an ANDA Paragraph IV filing.
Outside the United States, generic challenges would normally arise through national or regional procedures after commercial authorization and patent expiry. The withdrawal of the European authorization reduces the near-term incentive for such challenges unless a third party seeks a new national or decentralized approval based on available reference data.
What litigation affects filgotinib?
No major public patent litigation has defined filgotinib’s commercial history.
The principal legal and strategic event was the termination of the Galapagos-Gilead collaboration. The original 2019 agreement gave Gilead broad rights and included an upfront payment of approximately $1.1 billion, an equity investment of approximately $1.1 billion, and potential milestone payments. The parties later revised the relationship after filgotinib failed to secure U.S. approval. In 2024, Gilead returned commercial control to Galapagos and ended the collaboration (Gilead Sciences, 2019; Galapagos NV, 2024).
There is no equivalent public litigation record involving a major generic manufacturer, biosimilar developer, or patent invalidity campaign.
What formulations are protected by filgotinib patents?
The marketed product is an immediate-release oral tablet available principally in 100 mg and 200 mg strengths. Patent protection may cover:
- Filgotinib-containing pharmaceutical compositions
- Tablet formulations
- Solid-state forms and salts
- Oral dosing regimens
- Treatment of rheumatoid arthritis
- Treatment of ulcerative colitis
- Use in patients with specified safety or treatment histories
- Manufacturing intermediates and synthetic routes
Formulation patents are less commercially important than the compound patent because oral small-molecule tablets are comparatively easy to reproduce once the active ingredient and critical solid-state characteristics are understood. Their value depends on claim breadth, enforceability, and whether a generic can design around the formulation without compromising bioequivalence.
What is the competitive landscape for filgotinib?
Filgotinib competes in a crowded JAK inhibitor market where safety labeling, efficacy, route of administration, payer positioning, and prescriber familiarity influence uptake.
| Product |
Company |
JAK profile |
Main approved or commercial indications |
Competitive position |
| Rinvoq |
AbbVie |
JAK1 selective |
Rheumatoid arthritis, ulcerative colitis, Crohn’s disease and others |
Strong commercial leader |
| Xeljanz |
Pfizer |
JAK1/JAK3 |
Rheumatoid arthritis, ulcerative colitis and others |
Established but exposed to class warnings |
| Olumiant |
Eli Lilly |
JAK1/JAK2 |
Rheumatoid arthritis and other indications |
Broad immunology presence |
| Cibinqo |
Pfizer |
JAK1 selective |
Atopic dermatitis |
Dermatology-focused |
| Jyseleca |
Galapagos/Gilead |
JAK1 selective |
Rheumatoid arthritis, ulcerative colitis |
Withdrawn from EU market |
The FDA’s class-wide boxed warning for certain JAK inhibitors followed the ORAL Surveillance study of tofacitinib and affected the regulatory perception of the entire class. European regulators also imposed restrictions for higher-risk patients. These measures reduced the commercial flexibility of filgotinib and complicated differentiation based on selective JAK1 activity (FDA, 2021; EMA, 2023).
Filgotinib also faced a specific male fertility and testicular-safety issue. Although the MANTA studies did not show a meaningful deterioration in semen parameters relative to placebo over the principal study period, the need for dedicated reproductive monitoring increased development cost and prescribing complexity.
What market projection is realistic for filgotinib?
The realistic base case is declining or minimal branded revenue rather than renewed global growth.
Galapagos reported approximately €111 million in Jyseleca product sales for 2023, according to its annual reporting. That level was materially below the commercial potential originally associated with a global JAK1 launch and depended primarily on European access and selected international markets (Galapagos NV, 2024).
Scenario projection
| Scenario |
2025-2027 outlook |
Key drivers |
| Base case |
Near-zero to low tens of millions of euros annually |
EU withdrawal, limited residual sales, no U.S. approval |
| Upside case |
Modest regional revenue |
Continued Japanese access, successful rights transfer, limited niche prescribing |
| Downside case |
Rapid revenue collapse |
Supply discontinuation, reimbursement removal, substitution by competing JAK inhibitors and biologics |
| Long-term generic case |
Possible low-cost availability after national patent barriers fall |
Patent expiry, regulatory re-entry, commercial interest from generic manufacturers |
The former peak-sales opportunity was substantially reduced by four factors:
- The U.S. market was lost before launch.
- European JAK competition intensified.
- Safety restrictions affected the whole class.
- The EU authorization was withdrawn before the expected patent-protected commercial life ended.
A future value case could still exist for regional rights, manufacturing assets, or patent licensing. It would be based on low acquisition cost, residual approved-market access, and the possibility of generic or specialty commercialization. It would not support a conventional high-growth branded forecast.
What licensing deals involve filgotinib?
The central licensing transaction was the 2019 Galapagos-Gilead collaboration.
The agreement gave Gilead broad rights to develop and commercialize filgotinib and other Galapagos programs. Gilead paid:
- Approximately $1.1 billion in upfront consideration
- Approximately $1.1 billion for an equity investment in Galapagos
- Potential development, regulatory, and commercial milestones reported at up to approximately $1.7 billion
The collaboration was later narrowed after the FDA rejected the filgotinib application. Gilead returned rights and ended the collaboration in 2024. That reversal demonstrates the gap between early platform valuation and the eventual commercial value of the lead asset.
What generic entry risks exist for filgotinib?
Generic entry risk is low in the immediate term because the major approved European market has been withdrawn. The risk could rise if:
- Galapagos or a partner reintroduces the product in selected countries
- A national authorization remains active outside the European Union
- Core patents expire while clinical reference data remain usable
- A generic manufacturer acquires local rights or pursues an independent authorization
- Filgotinib becomes a low-cost alternative in markets with constrained access to biologics
Manufacturing is unlikely to be an insurmountable barrier. Filgotinib is an orally administered small molecule, and the active pharmaceutical ingredient does not require biologic-cell-line production. Barriers are more likely to involve process know-how, impurity control, solid-state form selection, bioequivalence, regulatory documentation, and country-specific patent enforcement.
Key Takeaways
- Filgotinib reached approval in the European Union and Japan but not the United States.
- Jyseleca was approved for rheumatoid arthritis and ulcerative colitis in Europe.
- The European marketing authorization was withdrawn in 2024 for commercial reasons.
- There is no U.S. Orange Book listing and no meaningful U.S. Paragraph IV litigation pathway.
- The patent estate covers the compound, formulations, dosing, methods of treatment, and manufacturing subject matter.
- Core protection is generally associated with the late 2020s or around 2030, depending on country and patent family.
- Filgotinib is exposed to generic competition rather than biosimilar competition.
- The realistic market outlook is residual regional revenue, not a renewed global launch.
- The main strategic value now lies in selected regional rights, manufacturing know-how, and patent assets.
FAQs
Is filgotinib still available in Europe?
The European marketing authorization was withdrawn in 2024 at the request of the marketing authorization holder. Commercial availability therefore depends on local wind-down arrangements and any subsequent national regulatory action.
Is filgotinib a biosimilar?
No. Filgotinib is a chemically synthesized small molecule. Any follow-on product would generally be regulated as a generic or under a comparable small-molecule pathway, not as a biosimilar.
Why was filgotinib not approved in the United States?
The FDA issued a complete response letter after reviewing the benefit-risk profile, long-term safety information, and reproductive-safety data. Gilead did not proceed to a U.S. approval and commercial launch.
Which drug is the closest commercial competitor to filgotinib?
Rinvoq, AbbVie’s selective JAK1 inhibitor, is the closest major commercial comparator based on mechanism and overlapping rheumatoid arthritis and ulcerative-colitis use. Xeljanz and Olumiant are broader class competitors.
Can a generic company launch filgotinib after European withdrawal?
Not automatically. A generic company would still need a valid regulatory pathway, a source of approved reference data, manufacturing capability, and freedom to operate around surviving compound, formulation, method-of-use, and process patents.
References
- European Commission. (2020). Jyseleca: EPAR product information and marketing authorization decision. https://health.ec.europa.eu
- European Medicines Agency. (2021). Jyseleca: Extension of indication for ulcerative colitis. https://www.ema.europa.eu
- European Medicines Agency. (2023). Janus kinase inhibitors: EMA recommendations for use in chronic inflammatory disorders. https://www.ema.europa.eu
- European Medicines Agency. (2024). Jyseleca: Withdrawal of marketing authorization. https://www.ema.europa.eu
- U.S. Food and Drug Administration. (2021). FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors. https://www.fda.gov
- Gilead Sciences, Inc. (2019). Gilead and Galapagos enter global research and development collaboration. https://www.gilead.com
- Galapagos NV. (2024). Annual report 2023 and strategic update on Jyseleca. https://www.glpg.com
